ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

ACADIA Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript

May 10, 2023 / 06:20PM GMT
Release Date Price: $21.65 (+1.03%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

Good morning. Welcome to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the Senior (inaudible) Analyst here. It's my pleasure to have our next presenting company, ACADIA Pharmaceuticals with me up here on stage. To my right is Steve Davis, who is, of course, CEO of the company. And to my left is Mark Schneyer, who is CFO. Steve and Mark, good morning. Thanks for coming to Vegas.

So maybe we could start off, Steve, with a quick overview of ACADIA, a 2-minute elevator pitch on the company, its background and then we can go straight into Q&A.

Stephen R. Davis
ACADIA Pharmaceuticals Inc. - CEO & Director

Perfect. So I'll try to keep it in 2 minutes and then we can spend a productive time in Q&A. So 4 things I'll touch on this morning. We have 2 commercial products today, NUPLAZID for Parkinson's disease psychosis and Daybue for Rett syndrome. So I'll give you just a brief snippet on each of those, and I'll talk about a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot